Lexicon Pharmaceuticals Inc (LXRX)

12.56
0.25 2.00
NASDAQ : Health Care
Prev Close 12.81
Open 12.81
Day Low/High 12.41 / 12.89
52 Wk Low/High 7.65 / 15.84
Volume 208.40K
Avg Volume 678.80K
Exchange NASDAQ
Shares Outstanding 105.58M
Market Cap 1.31B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 InTandem1 And InTandem2 Studies Of Sotagliflozin

Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 InTandem1 And InTandem2 Studies Of Sotagliflozin

- Patients on sotagliflozin 200 mg spent 1.3 hours longer in target glucose range per day than placebo

Interesting LXRX Put And Call Options For September 15th

Interesting LXRX Put And Call Options For September 15th

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading today, for the September 15th expiration.

Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

First -in-Class Oral Tryptophan Hydroxylase Inhibitor to be Considered for Approval in Europe for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy

Interesting LXRX Put And Call Options For August 18th

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the August 18th expiration.

Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 InTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Sotagliflozin Demonstrates Statistically Significant Benefit in Primary Endpoint

First Week of January 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2018 expiration.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017

Conference Call and Webcast to Follow

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

TheStreet Quant Rating: D (Sell)